Clinical trialNCT00753545CompletedPhase 2Interventional

Assessment of Efficacy of AZD2281 in Platinum Sensitive Relapsed Serous Ovarian Cancer

SponsorAstraZenecaEnrollment265Ovarian Cancer

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

The primary purpose of this study to determine if AZD2281 is effective and well tolerated in maintaining the improvement in your cancer after previous platinum-based chemotherapy

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.

Mika Sovak, BSc, MBCHB, MD
AstraZeneca
Study Director
clinicaltrials.gov ↗
Prof Jonathan A Lederman
University College, London
Principal Investigator
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

107 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

Australia

Research Site
Adelaide, Australia
Research Site
East Bentleigh, Australia
Research Site
Heidelberg, Australia
Research Site
Melbourne, Australia
Research Site
Nambour, Australia
Research Site
Randwick, Australia
Research Site
South Brisbane, Australia
Research Site
Toorak Gardens, Australia

Austria

Research Site
Innsbruck, Austria
Research Site
Vienna, Austria
Research Site
Wein, Austria

Belgium

Research Site
Brussels, Belgium
Research Site
Leuven, Belgium

Canada

Research Site
Vancouver, British Columbia, Canada
Research Site
Toronto, Ontario, Canada
Research Site
Québec, Quebec, Canada
Research Site
Sherbrooke, Quebec, Canada

Czechia

Research Site
Brno, Czechia
Research Site
Brno, Czechia
Research Site
Olomouc, Czechia
Research Site
Prague, Czechia

Estonia

Research Site
Tallinn, Estonia
Research Site
Tartu, Estonia

France

Research Site
Bordeaux, France
Research Site
Caen, France
Research Site
Lyon, France
Research Site
Nantes, France
Research Site
Paris, France
Research Site
Paris, France
Research Site
Reims, France

Germany

Research Site
Bonn, Germany
Research Site
Düsseldorf, Germany
Research Site
Essen, Germany
Research Site
Freiburg im Breisgau, Germany
Research Site
Göttingen, Germany
Research Site
Hanover, Germany
Research Site
Kiel, Germany
Research Site
Marburg, Germany
Research Site
München, Germany
Research Site
Rostock, Germany

67 more sites on the registry record.ClinicalTrials.gov ↗

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

AZD2281Matching placebo

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 28 Aug 2008
Primary completion: 30 Jun 2010
Completion: 12 Oct 2023
Last update posted: 3 Feb 2025
Registered enrollment: 265
Registry id: NCT00753545

Cross-registrations

EU-CTR / CTIS (EudraCT)2008-003439-18

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.